Lobe Sciences Ltd.
Lobe Sciences Ltd.
Lobe Sciences is a biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaboration with industry-leading partners, is engaged in novel research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolio, and intends to initiate the launch of Altemia®, a medical food designed to meet the needs of sickle cell patients globally.
Lobe Sciences Ltd. (LOBE)
Lobe Sciences Ltd. (LOBE)
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| RBC Capital Markets | 8,000 | 0.025 | 0.035 | 15,000 | RBC Capital Markets |
| National Bank Financial Inc. | 22,000 | 0.02 | 0.035 | 1,000 | Desjardins Securities Inc. |
| TD Securities Inc. | 23,000 | 0.02 | 0.035 | 20,000 | RBC Capital Markets |
| Desjardins Securities Inc. | 4,000 | 0.02 | 0.04 | 10,000 | RBC Capital Markets |
| RBC Capital Markets | 33,000 | 0.02 | 0.045 | 1,000 | Raymond James Ltd. |
| TD Securities Inc. | 12,000 | 0.02 | 0.055 | 9,000 | Scotia Capital Inc. |
| TD Securities Inc. | 12,000 | 0.02 | 0.055 | 14,000 | RBC Capital Markets |
| Canaccord Capital Corporation | 9,000 | 0.02 | 0.055 | 10,000 | Canaccord Capital Corporation |
| Canaccord Capital Corporation | 9,000 | 0.02 | 0.055 | 25,000 | Canaccord Capital Corporation |
| Canaccord Capital Corporation | 100,000 | 0.02 | 0.06 | 14,000 | TD Securities Inc. |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 1 | 8,000 | 0.025 | 0.035 | 36,000 | 3 |
| 9 | 224,000 | 0.02 | 0.04 | 10,000 | 1 |
| 6 | 220,000 | 0.015 | 0.045 | 1,000 | 1 |
| 4 | 251,000 | 0.01 | 0.055 | 58,000 | 4 |
| 5 | 193,000 | 0.005 | 0.06 | 18,000 | 2 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Apr 4, 13:30 | 0.025 | 0.00 | 1,000 | RBC Capital Markets | RBC Capital Markets | CSE |
| Apr 3, 14:06 | 0.025 | 0.00 | 1,000 | Raymond James Ltd. | TD Securities Inc. | CSE |
| Apr 3, 14:06 | 0.025 | 0.00 | 20,000 | CIBC World Markets Inc. | TD Securities Inc. | CSE |
| Apr 3, 14:06 | 0.025 | 0.00 | 14,000 | CIBC World Markets Inc. | TD Securities Inc. | CSE |
| Apr 3, 13:56 | 0.03 | 0.005 | 3,000 | Desjardins Securities Inc. | TD Securities Inc. | CSE |
Company Info
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
News release
News release
Bulletins
2022-0613 – Consolidation - Lobe Sciences Ltd. (LOBE)
le 9 juin/June 2022
Lobe Sciences Ltd. (the "Issuer") has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every six (6) pre-consolidated common shares.
As a result, the outstanding common shares of the Issuer will be reduced to approximately 38,230,000 common shares.
